NERV Stock Is on the Move, but Is It a Buy?

Published on September 6, 2022

Biopharmaceutical company Minerva Neurosciences (NERV) delivered considerable losses in its last quarter. Investors are increasingly concerned about the company’s massive debt burden and increased cash burn. Despite its limited earnings...

Continue reading on website
Other news

How to Quickly Adapt to Change and Future-Proof Your Business

September 6, 2022
In this episode he shares valuable lessons from history and today’s brightest entrepreneurs to help you quickly adapt to change and Future-Proof your business.

Looking to Hire a Marketer? Here's Why You Should Think Twice.

September 6, 2022
Successfully marketing your brand can be a challenge. Hiring a marketer may feel like the easiest and most sensible solution, but keep a few things in mind before you do it.